FibroGen (FGEN) Misses Q4 EPS by 53c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. GILD
9. SBUX
10. SNDK

Go back to FibroGen (FGEN) Misses Q4 EPS by 53c, Revenues Miss

FibroGen Reports Fourth Quarter and Full Year 2019 Financial Results

March 2, 2020 4:01 PM EST

Roxadustat NDA submission accepted with PDUFA date of December 20, 2020Pamrevlumab pivotal trials for treatment of idiopathic pulmonary fibrosis (IPF) and locally advanced unresectable pancreatic cancer (LAPC) underwayEnrique Conterno appointed Chief Executive Officer

SAN FRANCISCO, March 02, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the fourth quarter and full year of 2019 and provided an update on the companys recent developments.

I am thrilled to be joining FibroGen at such an important inflection point for the company. In 2019 we... More